KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Amgen (AMGN) over the last 17 years, with Q4 2025 value amounting to $1.6 billion.

  • Amgen's Cash from Operations fell 6640.12% to $1.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $10.0 billion, marking a year-over-year decrease of 1333.33%. This contributed to the annual value of $10.0 billion for FY2025, which is 1333.33% down from last year.
  • As of Q4 2025, Amgen's Cash from Operations stood at $1.6 billion, which was down 6640.12% from $4.7 billion recorded in Q3 2025.
  • In the past 5 years, Amgen's Cash from Operations ranged from a high of $4.8 billion in Q4 2024 and a low of $538.0 million during Q4 2023
  • For the 5-year period, Amgen's Cash from Operations averaged around $2.4 billion, with its median value being $2.3 billion (2021).
  • As far as peak fluctuations go, Amgen's Cash from Operations tumbled by 7969.04% in 2023, and later soared by 78680.3% in 2024.
  • Amgen's Cash from Operations (Quarter) stood at $2.8 billion in 2021, then fell by 5.66% to $2.6 billion in 2022, then tumbled by 79.69% to $538.0 million in 2023, then surged by 786.8% to $4.8 billion in 2024, then tumbled by 66.4% to $1.6 billion in 2025.
  • Its last three reported values are $1.6 billion in Q4 2025, $4.7 billion for Q3 2025, and $2.3 billion during Q2 2025.